Combined with our new finding that IL-17 inhibits T cell infiltration through the downregulation of CXCL9/10, it is now clear that IL-17 skews tumor immune environment towards an innate cell-dominant, tumor-promoting inflammation. Here, CXCL9 is linked to neoplasm.